Journal of Community Genetics

, Volume 1, Issue 4, pp 185–194

Points to consider in assessing and appraising predictive genetic tests

  • Wolf H. Rogowski
  • Scott D. Grosse
  • Jürgen John
  • Helena Kääriäinen
  • Alastair Kent
  • Ulf Kristofferson
  • Jörg Schmidtke
Commentary

Abstract

The use of predictive genetic tests is expanding rapidly. Given limited health care budgets and few national coverage decisions specifically for genetic tests, evidence of benefits and harms is a key requirement in decision making; however, assessing the benefits and harms of genetic tests raises a number of challenging issues. Frequently, evidence of medical benefits and harms is limited due to practical and ethical limitations of conducting meaningful clinical trials. Also, clinical endpoints frequently do not capture the benefit appropriately because the main purpose of many genetic tests is personal utility of knowing the test results, and costs of the tests and counseling can be insufficient indicators of the total costs of care. This study provides an overview of points to consider for the assessment of benefits and harms from genetic tests in an ethically and economically reflected manner. We discuss whether genetic tests are sufficiently exceptional to warrant exceptional methods for assessment and appraisal.

Keywords

Resource allocation Genetic testing Costs and cost analysis 

References

  1. Adair A, Hyde-Lay R, Einsiedel E, Caulfield T (2009) Technology assessment and resource allocation for predictive genetic testing: a study of the perspectives of Canadian genetic health care providers. BMC Med Ethics 10:6CrossRefPubMedGoogle Scholar
  2. Adams PC, Valberg LS (1999) Screening blood donors for hereditary hemochromatosis: decision analysis model comparing genotyping to phenotyping. Am J Gastroenterol 94:1593–1600CrossRefPubMedGoogle Scholar
  3. Allen KJ et al (2008) Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med 358:221–230CrossRefPubMedGoogle Scholar
  4. Anderson RT et al (2006) Impact of hemochromatosis screening in patients with indeterminate results: the hemochromatosis and iron overload screening study. Genet Med 8:681–687CrossRefPubMedGoogle Scholar
  5. Beauchamp TL, Childress JF (2009) Principles of biomedical ethics. Oxford University Press, OxfordGoogle Scholar
  6. Beery TA, Williams JK (2007) Risk reduction and health promotion behaviors following genetic testing for adult-onset disorders. Genet Test 11:111–123CrossRefPubMedGoogle Scholar
  7. Beran TM et al (2008) The trajectory of psychological impact in BRCA1/2 genetic testing: does time heal? Ann Behav Med 36:107–116CrossRefPubMedGoogle Scholar
  8. Bodamer OA, Hoffmann GF, Lindner M (2007) Expanded newborn screening in Europe 2007. J Inherit Metab Dis 30:439–444CrossRefPubMedGoogle Scholar
  9. Bos JM, Postma MJ, Annemans L (2005) Discounting health effects in pharmacoeconomic evaluations: current controversies. Pharmacoeconomics 23:639–649CrossRefPubMedGoogle Scholar
  10. Broadstock M, Michie S, Marteau T (2000) Psychological consequences of predictive genetic testing: a systematic review. Eur J Hum Genet 8:731–738CrossRefPubMedGoogle Scholar
  11. Brouwer WB, Culyer AJ, van Exel NJ, Rutten FF (2008) Welfarism vs. extra-welfarism. J Health Econ 27:325–338PubMedGoogle Scholar
  12. Buchanan AE, Brock DW (2007) From chance to choice: genetics and justice. Cambridge University Press, CambridgeGoogle Scholar
  13. Burnett L, McQueen MJ, Jonsson JJ, Torricelli F (2007) IFCC position paper: report of the IFCC taskforce on ethics: introduction and framework. Clin Chem Lab Med 45:1098–1104CrossRefPubMedGoogle Scholar
  14. Claxton K et al (2006) Discounting and cost-effectiveness in NICE—stepping back to sort out a confusion. Health Econ 15:1–4CrossRefPubMedGoogle Scholar
  15. Cohn DM, Vansenne F, Kaptein AA, De Borgie CA, Middeldorp S (2008) The psychological impact of testing for thrombophilia: a systematic review. J Thromb Haemost 6:1099–1104CrossRefPubMedGoogle Scholar
  16. de Jong A, Dondorp WJ, de Die-Smulders CE, Frints SG, de Wert GM (2010) Non-invasive prenatal testing: ethical issues explored. Eur J Hum Genet 18:272–277CrossRefPubMedGoogle Scholar
  17. Denny CC, Wilfond BS, Peters JA, Giri N, Alter BP (2008) All in the family: disclosure of “unwanted” information to an adolescent to benefit a relative. Am J Med Genet A 146A:2719–2724CrossRefPubMedGoogle Scholar
  18. Donaldson C, Mason H, Shackley P (2006) Contingent Valuation in Health Care In: Jones, AM (ed) The Elgar companion to health economics, Elgar, Cheltenham u.a, pp 392–404Google Scholar
  19. Douma KF, Aaronson NK, Vasen HF, Bleiker EM (2008) Psychosocial issues in genetic testing for familial adenomatous polyposis: a review of the literature. Psychooncology 17:737–745CrossRefPubMedGoogle Scholar
  20. Drummond MF (2005) Methods for the economic evaluation of health care programmes. Oxford University Press, OxfordGoogle Scholar
  21. El-Serag HB, Inadomi JM, Kowdley KV (2000) Screening for hereditary hemochromatosis in siblings and children of affected patients. A cost-effectiveness analysis. Ann Intern Med 132:261–269PubMedGoogle Scholar
  22. Foster C et al (2007) Predictive genetic testing for BRCA1/2 in a UK clinical cohort: 3-year follow-up. Br J Cancer 96:718–724CrossRefPubMedGoogle Scholar
  23. Frederick S, Loewenstein G, O’Donoghue T (2002) Time discounting and time preference: a critical review. J Econ Lit 40(2):351–401CrossRefGoogle Scholar
  24. Gargiulo M et al (2009) Long-term outcome of presymptomatic testing in Huntington disease. Eur J Hum Genet 17:165–171CrossRefPubMedGoogle Scholar
  25. Garrison L, Towse A (2003) The drug budget silo mentality in Europe: an overview. Value Health 6(Suppl 1):S1–S9CrossRefPubMedGoogle Scholar
  26. Gazelle GS, McMahon PM, Siebert U, Beinfeld MT (2005) Cost-effectiveness analysis in the assessment of diagnostic imaging technologies. Radiology 235:361–370CrossRefPubMedGoogle Scholar
  27. Gold MR (1996) In: Gold MR (ed) Cost-effectiveness in health and medicine. Oxford University Press, New YorkGoogle Scholar
  28. Gravelle H, Brouwer W, Niessen L, Postma M, Rutten F (2007) Discounting in economic evaluations: stepping forward towards optimal decision rules. Health Econ 16:307–317CrossRefPubMedGoogle Scholar
  29. Grosse SD, Khoury MJ (2006) What is the clinical utility of genetic testing? Genet Med 8:448–450CrossRefPubMedGoogle Scholar
  30. Grosse SD, Wordsworth S, Payne K (2008) Economic methods for valuing the outcomes of genetic testing: beyond cost-effectiveness analysis. Genet Med 10:648–654CrossRefPubMedGoogle Scholar
  31. Grosse SD, McBride CM, Evans JP, Khoury MJ (2009) Personal utility and genomic information: look before you leap. Genet Med 11:575–576CrossRefPubMedGoogle Scholar
  32. Grosse SD, Kalman L, Khoury MJ (2010a) Evaluation of the validity and utility of genetic testing for rare diseases. Adv Exp Med Biol 686:115–131CrossRefGoogle Scholar
  33. Grosse SD et al (2010b) Population screening for genetic disorders in the 21st Century: evidence, economics, and ethics. Public Health Genomics 13(2):106–115CrossRefPubMedGoogle Scholar
  34. Ioannidis JP, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG (2001) Replication validity of genetic association studies. Nat Genet 29:306–309CrossRefPubMedGoogle Scholar
  35. Janssens AC, van Duijn CM (2008) Genome-based prediction of common diseases: advances and prospects. Hum Mol Genet 17:R166–R173CrossRefPubMedGoogle Scholar
  36. Javaher P et al (2008) EuroGentest: DNA-based testing for heritable disorders in Europe. Community Genet 11:75–120CrossRefPubMedGoogle Scholar
  37. Krawczak M, Caliebe A, Croucher PJ, Schmidtke J (2007) On the testing load incurred by cascade genetic carrier screening for Mendelian disorders: a brief report. Genet Test 11:417–419CrossRefPubMedGoogle Scholar
  38. Kress H (2007) Preimplantation genetic diagnosis. Ethical, social and legal aspects. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 50:157–167CrossRefPubMedGoogle Scholar
  39. Larsson MU, Luszcz MA, Bui TH, Wahlin TB (2006) Depression and suicidal ideation after predictive testing for Huntington’s disease: a 2-year follow-up study. J Genet Couns 15:361–374CrossRefPubMedGoogle Scholar
  40. Licklederer C, Wolff G, Barth J (2008) Mental health and quality of life after genetic testing for Huntington disease: a long-term effect study in Germany. Am J Med Genet A 146A:2078–2085CrossRefPubMedGoogle Scholar
  41. McDonald HP, Garg AX, Haynes RB (2002) Interventions to enhance patient adherence to medication prescriptions: scientific review. Jama 288:2868–2879CrossRefPubMedGoogle Scholar
  42. McGuire AL, Burke W (2008) An unwelcome side effect of direct-to-consumer personal genome testing: raiding the medical commons. JAMA 300:2669–2671CrossRefPubMedGoogle Scholar
  43. Murray TH (1997) Genetic exceptionalism and “future diaries” is genetic information different from other medical information? In: Rothstein M (ed) Genetic secrets: protecting privacy and confidentiality in the genetic era. Yale University Press, New Haven, pp 60–73Google Scholar
  44. Mvundura M, Grosse SD, Hampel H, Palomaki GE (2010) The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. Genet Med 12:93–104CrossRefPubMedGoogle Scholar
  45. Payne K et al (2008) Outcome measurement in clinical genetics services: a systematic review of validated measures. Value Health 11:497–508CrossRefPubMedGoogle Scholar
  46. Potter BK et al (2008) Guidance for considering ethical, legal, and social issues in health technology assessment: application to genetic screening. Int J Technol Assess Health Care 24:412–422CrossRefPubMedGoogle Scholar
  47. Regier DA, Friedman JM, Makela N, Ryan M, Marra CA (2009) Valuing the benefit of diagnostic testing for genetic causes of idiopathic developmental disability: willingness to pay from families of affected children. Clin Genet 75:514–521CrossRefPubMedGoogle Scholar
  48. Riegert-Johnson DL, Macaya D, Hefferon TW, Boardman LA (2008) The incidence of duplicate genetic testing. Genet Med 10:114–116CrossRefPubMedGoogle Scholar
  49. Ries NM, Hyde-Lay R, Caulfield T (2010) Willingness to pay for genetic testing: a study of attitudes in a Canadian population. Public Health Genomics 13:292–300CrossRefPubMedGoogle Scholar
  50. Rogowski W (2006) Genetic screening by DNA technology. A systematic review of health economic evidence. Int J Technol Assess Health Care 22:327–337CrossRefPubMedGoogle Scholar
  51. Rogowski W (2007) Current impact of gene technology on healthcare. A map of economic assessments. Health Policy 80:340–357CrossRefPubMedGoogle Scholar
  52. Rogowski WH (2009) The cost-effectiveness of screening for hereditary hemochromatosis in Germany: a remodeling study. Med Decis Mak 29:224–238CrossRefGoogle Scholar
  53. Rogowski WH, Hartz SC, John JH (2008) Clearing up the hazy road from bench to bedside: a framework for integrating the fourth hurdle into translational medicine. BMC Health Serv Res 8:1–12CrossRefGoogle Scholar
  54. Rogowski WH, Grosse SD, Khoury MJ (2009a) Challenges of translating genetic tests into clinical and public health practice. Nat Rev Genet 10:489–495CrossRefPubMedGoogle Scholar
  55. Rogowski W, Landauer M, John, J (2009) The legal context of decision analytic modelling for economic evaluation in Germany (angenommen zur Publikation in: Gesundheitswesen)Google Scholar
  56. Schmidtke J, Pabst B, Nippert I (2005) DNA-based genetic testing is rising steeply in a national health care system with open access to services: a survey of genetic test use in Germany, 1996-2002. Genet Test 9:80–84CrossRefPubMedGoogle Scholar
  57. Smith AW et al (2008) Psychological distress and quality of life associated with genetic testing for breast cancer risk. Psychooncology 17:767–773CrossRefPubMedGoogle Scholar
  58. Sugarman J, Sulmasy DP (2001) Methods in medical ethics. Georgetown University Press, Washington, DCGoogle Scholar
  59. Teutsch SM et al (2009) The evaluation of genomic applications in practice and prevention (EGAPP) initiative: methods of the EGAPP working group. Genet Med 11:3–14CrossRefPubMedGoogle Scholar
  60. van der Net JB, Janssens AC, Sijbrands EJ, Steyerberg EW (2009) Value of genetic profiling for the prediction of coronary heart disease. Am Heart J 158:105–110CrossRefPubMedGoogle Scholar
  61. van Hoek M et al (2008) Predicting type 2 diabetes based on polymorphisms from genome-wide association studies: a population-based study. Diabetes 57:3122–3128CrossRefPubMedGoogle Scholar
  62. Wasson K, Cook ED, Helzlsouer K (2006) Direct-to-consumer online genetic testing and the four principles: an analysis of the ethical issues. Ethics Med 22:83–91PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Wolf H. Rogowski
    • 1
    • 2
  • Scott D. Grosse
    • 3
  • Jürgen John
    • 1
  • Helena Kääriäinen
    • 4
  • Alastair Kent
    • 5
  • Ulf Kristofferson
    • 6
  • Jörg Schmidtke
    • 7
  1. 1.Helmholtz Zentrum MünchenGerman Research Center for Environmental Health (GmbH)NeuherbergGermany
  2. 2.Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, Clinical CenterLudwig Maximilians UniversityMunichGermany
  3. 3.National Center on Birth Defects and Developmental DisabilitiesCenters for Disease Control and PreventionAtlantaUSA
  4. 4.National Institute for Health and WelfareHelsinkiFinland
  5. 5.Genetic Interest GroupLondonUK
  6. 6.Department of Clinical GeneticsUniversity and Regional Laboratories and Lund University, University HospitalLundSweden
  7. 7.Institut fuer HumangenetikMedizinische Hochschule HannoverHannoverGermany

Personalised recommendations